<span item_type="fundamental" item_id="2549217ce6100c6823e3471ce1d069fb" counter_id="ST/US/XTNT" env="prod"></span><span item_type="announcement" item_id="581348655498138369" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 33.26 B, beating the estimate of USD 32.7 M.</p><p>EPS: As of FY2025 Q3, the actual value is USD 0.01.</p><p>EBIT: As of FY2025 Q3, the actual value is USD 3.445 B.</p><p></p><h3>Financial Metrics by Segment</h3><h4>Revenue</h4><ul><li><strong>Total Revenue</strong>: $33.3 million for Q3 2025, up from $27.9 million in Q3 2024. For the nine months ended September 30, 2025, total revenue was $101.6 million, up from $85.8 million in the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1453593/000149315225021512/form10-q.htm"></span></li><li><strong>Product Revenue</strong>: $27.8 million for Q3 2025, compared to $27.9 million in Q3 2024. For the nine months ended September 30, 2025, product revenue was $87.5 million, up from $85.8 million in the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1453593/000149315225021512/form10-q.htm"></span></li><li><strong>License Revenue</strong>: $5.5 million for Q3 2025, compared to $0 in Q3 2024. For the nine months ended September 30, 2025, license revenue was $14.1 million, compared to $0 in the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1453593/000149315225021512/form10-q.htm"></span></li></ul><h4>Operational Metrics</h4><ul><li><strong>Gross Profit</strong>: $22.0 million for Q3 2025, up from $16.3 million in Q3 2024. For the nine months ended September 30, 2025, gross profit was $66.5 million, up from $52.2 million in the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1453593/000149315225021512/form10-q.htm"></span></li><li><strong>Gross Margin</strong>: 66.1% for Q3 2025, up from 58.4% in Q3 2024. For the nine months ended September 30, 2025, gross margin was 65.5%, up from 60.9% in the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1453593/000149315225021512/form10-q.htm"></span></li><li><strong>Net Income (Loss)</strong>: $1.3 million for Q3 2025, compared to -$5.0 million in Q3 2024. For the nine months ended September 30, 2025, net income was $4.9 million, compared to -$13.3 million in the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1453593/000149315225021512/form10-q.htm"></span></li><li><strong>Operating Expenses</strong>: $19.5 million for Q3 2025, down from $20.1 million in Q3 2024. For the nine months ended September 30, 2025, operating expenses were $58.3 million, down from $62.4 million in the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1453593/000149315225021512/form10-q.htm"></span></li><li><strong>Interest Expense</strong>: $0.9 million for Q3 2025, down from $1.2 million in Q3 2024. For the nine months ended September 30, 2025, interest expense was $3.0 million, down from $3.0 million in the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1453593/000149315225021512/form10-q.htm"></span></li></ul><h4>Cash Flow</h4><ul><li><strong>Net Cash Provided by Operating Activities</strong>: $7.2 million for the nine months ended September 30, 2025, compared to -$12.6 million in the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1453593/000149315225021512/form10-q.htm"></span></li><li><strong>Net Cash Provided by Investing Activities</strong>: $3.2 million for the nine months ended September 30, 2025, compared to -$3.2 million in the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1453593/000149315225021512/form10-q.htm"></span></li><li><strong>Net Cash Used in Financing Activities</strong>: -$6.0 million for the nine months ended September 30, 2025, compared to $16.9 million in the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1453593/000149315225021512/form10-q.htm"></span></li></ul><h4>Unique Metrics</h4><ul><li><strong>Advances from Pending Sale of Coflex/CoFix Assets and International Hardware Business</strong>: $5.0 million as of September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1453593/000149315225021512/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><h4>Core Business Focus</h4><ul><li><strong>Growth Initiatives</strong>: Focus on introducing new products, expanding distribution network, penetrating adjacent markets, and leveraging growth platform with technology and strategic acquisitions.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1453593/000149315225021512/form10-q.htm"></span></li><li><strong>New Product Launches</strong>: Recent launches include CollagenX™, OsteoFactor Pro™, and Trivium™.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1453593/000149315225021512/form10-q.htm"></span></li></ul><h4>Non-Core Business</h4><ul><li><strong>Pending Sale of Coflex/CoFix Assets and International Hardware Business</strong>: Expected to close in Q4 2025, subject to financing by the buyer. Total purchase price of $17.5 million for Coflex/CoFix assets and $1.7 million for Paradigm Spine GmbH.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1453593/000149315225021512/form10-q.htm"></span></li></ul><h4>Priority</h4><ul><li><strong>Revenue Growth</strong>: Emphasis on increasing revenue through new product introductions and expanding market reach.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1453593/000149315225021512/form10-q.htm"></span></li><li><strong>Operational Efficiency</strong>: Focus on reducing costs and improving gross margins through internal production and strategic initiatives.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1453593/000149315225021512/form10-q.htm"></span></li></ul>

Xtant Med | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 33.26 B